TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Insulin Therapy With Enhanced Care Management and Peer Support
Brief Summary: VA diabetes patients often have difficulty managing their self-care and accessing clinic-based services; many also lack social support to help them meet the demands of their illness. Enhanced support is especially important when undertaking and sustaining new challenging self-care tasks, such as initiating or intensifying insulin treatment regimens. Although some VAs have implemented telephone nurse care management programs supported by automated calling services, many are reluctant to adopt these models due to nursing shortages.


Options:
A: Arm Label: Reciprocal Diabetes Peer Support program; Type: EXPERIMENTAL; Interventions: Behavioral: Reciprocal Diabetes Peer Support Program, Behavioral: group outpatient counseling visits | Arm Label: Nurse Case Management; Type: OTHER; Interventions: Behavioral: Nurse Case management | Intervention Type: BEHAVIORAL; Name: Reciprocal Diabetes Peer Support Program; Assigned to Arm(s): Reciprocal Diabetes Peer Support program | Intervention Type: BEHAVIORAL; Name: Nurse Case management; Assigned to Arm(s): Nurse Case Management | Intervention Type: BEHAVIORAL; Name: group outpatient counseling visits; Assigned to Arm(s): Reciprocal Diabetes Peer Support program
B: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: In Home Health Messaging Device | Intervention Type: BEHAVIORAL; Name: In Home Health Messaging Device; Assigned to Arm(s): Arm 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Full drug coverage | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual coverage | Intervention Type: OTHER; Name: Full drug coverage; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual coverage; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Comprehensive pharmacy care program; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Insulin Therapy With Enhanced Care Management and Peer Support
Brief Summary: VA diabetes patients often have difficulty managing their self-care and accessing clinic-based services; many also lack social support to help them meet the demands of their illness. Enhanced support is especially important when undertaking and sustaining new challenging self-care tasks, such as initiating or intensifying insulin treatment regimens. Although some VAs have implemented telephone nurse care management programs supported by automated calling services, many are reluctant to adopt these models due to nursing shortages.


Options:
A: Arm Label: Reciprocal Diabetes Peer Support program; Type: EXPERIMENTAL; Interventions: Behavioral: Reciprocal Diabetes Peer Support Program, Behavioral: group outpatient counseling visits | Arm Label: Nurse Case Management; Type: OTHER; Interventions: Behavioral: Nurse Case management | Intervention Type: BEHAVIORAL; Name: Reciprocal Diabetes Peer Support Program; Assigned to Arm(s): Reciprocal Diabetes Peer Support program | Intervention Type: BEHAVIORAL; Name: Nurse Case management; Assigned to Arm(s): Nurse Case Management | Intervention Type: BEHAVIORAL; Name: group outpatient counseling visits; Assigned to Arm(s): Reciprocal Diabetes Peer Support program
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Breaking Down Barriers | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breaking Down Barriers | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Breaking Down Barriers | Intervention Type: BEHAVIORAL; Name: Breaking Down Barriers; Assigned to Arm(s): 1, 2, 3
C: Intervention Type: BEHAVIORAL; Name: Nurse Case Management intervention; Assigned to Arm(s): N/A
D: Arm Label: Geriatric Diabetes Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral | Arm Label: Atention Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral; Assigned to Arm(s): Geriatric Diabetes Team Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Risankizumab; Type: EXPERIMENTAL; Interventions: Drug: Risankizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risankizumab; Assigned to Arm(s): Risankizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Abatacept (30/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (10/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (3/3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept (10/10), Abatacept (3/3), Abatacept (30/10) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)
B: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: ABP 501; Type: EXPERIMENTAL; Interventions: Biological: ABP 501 | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: ABP 501; Assigned to Arm(s): ABP 501
D: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 2 (Q4W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 3 (Q12W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3; Assigned to Arm(s): 80 mg Ixekizumab Dosing Regimen 2 (Q4W), 80 mg Ixekizumab Dosing Regimen 3 (Q12W), 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)
D: Arm Label: ABP 501; Type: EXPERIMENTAL; Interventions: Biological: ABP 501 | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: ABP 501; Assigned to Arm(s): ABP 501

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study
Brief Summary: The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic events. Demonstration of a favorable benefit:risk profile could lead to significant reduction in this serious and sometimes fatal complication of ongoing cancer and its treatment.


Options:
A: Arm Label: Cohort 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 1: Apixaban, 5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 1: Apixaban, 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 1: Apixaban, 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2: Apixaban, 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Cohort 1: Apixaban, 10 mg, Cohort 1: Apixaban, 20 mg, Cohort 1: Apixaban, 5 mg, Cohort 2: Apixaban, 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Placebo, Cohort 2: Placebo
B: Arm Label: Group 1: Dalteparin; Type: EXPERIMENTAL; Interventions: Drug: Dalteparin | Arm Label: Group 2: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Group 1: Dalteparin
C: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin, Drug: chemotherapy with LMWH - enoxaparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: only chemotherapy | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: chemotherapy with LMWH - enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: only chemotherapy; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study
Brief Summary: The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic events. Demonstration of a favorable benefit:risk profile could lead to significant reduction in this serious and sometimes fatal complication of ongoing cancer and its treatment.


Options:
A: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
B: Arm Label: Cohort 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 1: Apixaban, 5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 1: Apixaban, 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 1: Apixaban, 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2: Apixaban, 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Cohort 1: Apixaban, 10 mg, Cohort 1: Apixaban, 20 mg, Cohort 1: Apixaban, 5 mg, Cohort 2: Apixaban, 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Placebo, Cohort 2: Placebo
C: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): A, B, C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Irinotecan, Leucovorin, 5-FU (ILF) Versus ILF Plus Cisplatin (PILF) Combination Chemotherapy in Patients With Advanced Gastric Cancer
Brief Summary: To compare the combination of irinotecan, leucovorin and 5-FU (ILF) with ILF plus cisplatin (PILF) as first-line chemotherapy in patients with measurable metastatic gastric cancer.


Options:
A: Arm Label: Standard Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Palliative Care Group | Arm Label: Integrated Palliative Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Integrated Palliative Care Intervention | Intervention Type: OTHER; Name: Standard Palliative Care Group; Assigned to Arm(s): Standard Palliative Care Group | Intervention Type: OTHER; Name: Integrated Palliative Care Intervention; Assigned to Arm(s): Integrated Palliative Care Group
B: Arm Label: EOX; Type: ACTIVE_COMPARATOR; Interventions: Other: EOX | Arm Label: mDCF; Type: ACTIVE_COMPARATOR; Interventions: Other: mDCF | Intervention Type: OTHER; Name: EOX; Assigned to Arm(s): EOX | Intervention Type: OTHER; Name: mDCF; Assigned to Arm(s): mDCF
C: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Capecitabine, Drug: Cisplatin, Drug: 5-fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Cisplatin, Drug: Placebo, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Bevacizumab, Placebo
D: Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Myopia Evaluation Trial 2 (COMET2): A Randomized Trial of the Effect of Progressive Addition Lenses Versus Single Vision Lenses on Low Myopia Associated With Large Accommodative Lags and Near Esophoria in Children
Brief Summary: The purpose of the study is to determine if progressive addition lenses (PALs) versus single vision lenses (SVLs) slow the progression of low myopia in children with poor accommodative responses (i.e., large accommodative lags) and near esophoria.


Options:
A: Arm Label: Progressive addition lenses (PALs); Type: ACTIVE_COMPARATOR; Interventions: Device: Progressive Addition Lenses (PALs) | Arm Label: Single vision lenses (SVLs); Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: Progressive Addition Lenses (PALs); Assigned to Arm(s): Progressive addition lenses (PALs) | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): Single vision lenses (SVLs)
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Outdoor activity; Type: EXPERIMENTAL; Interventions: Behavioral: Outdoor activity | Intervention Type: BEHAVIORAL; Name: Outdoor activity; Assigned to Arm(s): Outdoor activity
C: Arm Label: auricular acupoint stimulation; Type: EXPERIMENTAL; Interventions: Drug: Atropine, Device: auricular acupoint stimulation | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine, auricular acupoint stimulation | Intervention Type: DEVICE; Name: auricular acupoint stimulation; Assigned to Arm(s): auricular acupoint stimulation
D: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Myopia Evaluation Trial 2 (COMET2): A Randomized Trial of the Effect of Progressive Addition Lenses Versus Single Vision Lenses on Low Myopia Associated With Large Accommodative Lags and Near Esophoria in Children
Brief Summary: The purpose of the study is to determine if progressive addition lenses (PALs) versus single vision lenses (SVLs) slow the progression of low myopia in children with poor accommodative responses (i.e., large accommodative lags) and near esophoria.


Options:
A: Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals
B: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A
C: Arm Label: Contact Lens; Type: EXPERIMENTAL; Interventions: Device: Soft contact lenses | Arm Label: Spectacle; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: Soft contact lenses; Assigned to Arm(s): Contact Lens | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle
D: Arm Label: Progressive addition lenses (PALs); Type: ACTIVE_COMPARATOR; Interventions: Device: Progressive Addition Lenses (PALs) | Arm Label: Single vision lenses (SVLs); Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: Progressive Addition Lenses (PALs); Assigned to Arm(s): Progressive addition lenses (PALs) | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): Single vision lenses (SVLs)

Answer: D